A study evaluating influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

Trial Profile

A study evaluating influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Rotigotine (Primary) ; Omeprazole
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors UCB
  • Most Recent Events

    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top